Skip to content
Ad
Ad
Value Science Weekly — health economics and market access, in your inbox
→
Trending
HTA
Health AI
Drug Pricing
Oncology
Search Syenza News
Search
Partner with us
Newsletter
Home
Topics
HTA
HTA Policies
Cost-Effectiveness Analysis
Health Economic Evaluations
Health Policy
Healthcare Access
Health Equity & Access
Reimbursement Policy
Value-Based Healthcare
Real-World Evidence
Clinical Trials
Oncology & Cancer Research
AI & Machine Learning
Drug Safety
All topics →
Regions
Europe
North America
Sub-Saharan Africa
Middle East & North Africa
Asia
Latin America
Global
Events
Upcoming Events
Event Coverage
About
Visit Syenza
Home
/
Voclosporin
Category
Voclosporin
1 article in this topic.
Ad
Ad
Articles in this category
5/13/2023
New treatment option for active lupus nephritis!
Clinical trials show that using voclosporin with mycophenolate mofetil is more effective at stopping lupus nephritis from getting worse than mycophenolate mofetil alone. This option is recommended for treating active class 3 to 5 lupus nephritis in adults. The cost-effectiveness estimates are within what NICE considers acceptable for NHS resources.
Read Article →
Related topics
Clinical Practice
1
Clinical Trials
1
Diseases
1
Europe
1
Lupus Nephritis
1
Middle East And North Africa
1
